---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-100228"
form_type: "8-K"
ticker: "TMDX"
cik: "0001756262"
company_name: "TransMedics Group, Inc."
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T23:08:36.835072+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TransMedics Q2 revenue $157.4M (+38% YoY), net income $34.9M; raises FY2025 guidance

## Summary
- Revenue $157.4M vs $114.3M YoY (+38%); net income $34.9M ($0.92 diluted EPS) vs $12.2M.
- Raises full-year 2025 revenue guidance to $585M-$605M from $565M-$585M (35% midpoint growth).
- Gross margin 61% consistent YoY; operating expenses $60.0M up from $56.8M on R&D investment.
- Cash $400.6M; received conditional IDE approval from FDA for Next-Gen OCS Lung trial.
- Launched OCS NOP digital ecosystem NOP ACCESS across major U.S. transplant programs.

## SEC filing metadata
- accession: 0000950170-25-100228
- form_type: 8-K
- ticker: TMDX
- cik: 0001756262
- company_name: TransMedics Group, Inc.
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1756262/000095017025100228/0000950170-25-100228-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1756262/000095017025100228/tmdx-20250730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-100228
- JSON: https://secwatch.observer/filing/0000950170-25-100228.json
- Plain text: https://secwatch.observer/filing/0000950170-25-100228.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.